In this study, we demonstrated that a heterozygous AD mutation in LZTR1 activates MAPK signaling and that trametinib treatment ameliorates cardiac hypertrophy in Lztr1R409C/+ mice (Figure 5 and Figure 6). This evidence concerns the gene LZTR1 and cardiac hypertrophy.